Lesniak et colleagues tested out the generation 4 PSMA-targeted polyamidoamine (PAMAM) dendrimers [G4(MP-KEU)] radiolabeled with 64Cu and 111In in prostate cancer (PCa) mice model [33]. This evidence concerns the gene FOLH1 and prostate carcinoma.